Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 4/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124567 | 0.98 | KMT2A (0.54) | KMT2AHTTMEN1POLBMAPT | |
| SCHEMBL30024828 | 0.98 | KMT2A (0.54) | KMT2AHTTMEN1POLBMAPT | |
| SCHEMBL7934127 | 0.78 | KMT2A (0.54) | KMT2AHTTMEN1POLBMAPT | |
| SCHEMBL15052994 | 0.77 | TRIM24 (0.47) | KMT2AHTTERN1DYRK1ATRIM24 | |
| SCHEMBL28518576 | 0.75 | ERN1 (0.41) | KMT2AHTTERN1DYRK1ATRIM24 | |
| SCHEMBL24609208 | 0.73 | HTT (0.30) | KMT2AHTT | |
| SCHEMBL6856791 | 0.73 | HTT (0.30) | KMT2AHTT | |
| SCHEMBL2214871 | 0.73 | ERN1 (0.39) | KMT2AHTTMEN1MAPTSMN1; SMN2 | |
| SCHEMBL17421095 | 0.73 | ERN1 (0.39) | KMT2AHTTMEN1SMN1; SMN2ERN1 | |
| SCHEMBL741314 | 0.73 | ERN1 (0.39) | KMT2AHTTERN1DYRK1ATRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004099-B1 | TETRAHYDROPYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2023-04-19 | — | — | EP | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| EP-3004099-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-04-13 | — | — | EP | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-9062075-B2 | Tetrahydropyridine derivatives as FabI inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-23 | — | — | US | disclosed |
| US-9051321-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2015-06-09 | — | — | US | disclosed |
| WO-2014195844-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FabI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-12-11 | — | — | WO | disclosed |
| US-20140357617-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2014-12-04 | — | — | US | disclosed |
| US-8846711-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20140275019-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FABI INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-20110124633-A1 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy | BERMAN JUDD | 2011-05-26 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-7790709-B2 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| EP-1608377-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARM INC (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-20060183908-A1 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-08-17 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| EP-1608377-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | Affinium Pharmaceuticals, Inc. (CA) | 2005-12-28 | — | — | EP | disclosed |
| EP-1575951-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | Affinium Pharmaceuticals, Inc. (CA) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004052890-A1 | HETEROCYCLIC COMPOUNDS, METHODS OF MAKING THEM AND THEIR USE IN THERAPY | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183908-A1 | inhibitors of bacterial enzymes such as (E)-3-(3,3-Dimethyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido [2,3-e][1,4]diazepin-7-yl)-N-methyl-N-(3-methyl-benzofuran-2-ylmethyl)acrylamide, used as antibiotics | AADAC, AZI2, DCXR | KMT2A 752/4885HTT 4455/4885MEN1 4372/4885 |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | KMT2A 4479/4885HTT 18/4885MEN1 1175/4885 |
| US-20110124633-A1 | Heterocyclic Compounds, Methods of Making Them and Their Use in Therapy | NQO1, AADAC, SDHA | KMT2A 3368/4885HTT 861/4885MEN1 969/4885 |
| US-20140357617-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | KMT2A 4479/4885HTT 18/4885MEN1 1175/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | KMT2A 4353/4885HTT 2878/4885MEN1 2222/4885 |
| US-20140275019-A1 | TETRAHYDROPYRIDINE DERIVATIVES AS FABI INHIBITORS | FAR1, QDPR, DHFR | KMT2A 2907/4885HTT 1881/4885MEN1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.